{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T03:32:30Z","timestamp":1783481550536,"version":"3.55.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s12885-016-2054-2","type":"journal-article","created":{"date-parts":[[2016,1,19]],"date-time":"2016-01-19T13:22:27Z","timestamp":1453209747000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Trabectedin for inoperable or recurrent soft tissue sarcoma in adult patients: a retrospective cohort study"],"prefix":"10.1186","volume":"16","author":[{"given":"Fernando A.","family":"Angarita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda J.","family":"Cannell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albiruni R.","family":"Abdul Razak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendan C.","family":"Dickson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin E.","family":"Blackstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,1,19]]},"reference":[{"key":"2054_CR1","unstructured":"Surveillance, epidemiology, and end results (SEER) program ( www.seer.cancer.gov ) SEER*Stat database: Incidence - SEER 9 Regs Research Data, Nov 2010 Sub (1973\u20132008)\u2009<\u2009Katrina\/Rita population adjustment\u2009>\u2009\u2212 Linked to County Attributes - Total U.S., 1969\u20132009 counties, National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, Released April 2011, based on the November 2010 submission."},{"key":"2054_CR2","first-page":"128","volume-title":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines(R)). Version I","author":"National Comprehensive Cancer Network (NCCN)","year":"2015","unstructured":"National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines(R)). Version I. 2015. p. 128."},{"issue":"Suppl 3","key":"2054_CR3","doi-asserted-by":"crossref","first-page":"iii102","DOI":"10.1093\/annonc\/mdu254","volume":"25","author":"ESMO\/European Sarcoma Network Working Group","year":"2014","unstructured":"ESMO\/European Sarcoma Network Working Group. Soft tissue and visceral sarcomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25 Suppl 3:iii102\u201312.","journal-title":"Ann Oncol"},{"key":"2054_CR4","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1200\/JCO.1999.17.1.150","volume":"17","author":"M Glabbeke Van","year":"1999","unstructured":"Van Glabbeke M, van Oosterom AT, Oosterhuis JW, et al. Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens--a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol. 1999;17:150\u20137.","journal-title":"J Clin Oncol"},{"key":"2054_CR5","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ejca.2009.09.022","volume":"46","author":"S Sleijfer","year":"2010","unstructured":"Sleijfer S, Ouali M, van Glabbeke M, et al. Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG). Eur J Cancer. 2010;46:72\u201383.","journal-title":"Eur J Cancer"},{"key":"2054_CR6","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1039\/b808331m","volume":"26","author":"C Cuevas","year":"2009","unstructured":"Cuevas C, Francesch A. Development of Yondelis (trabectedin, ET-743). A semisynthetic process solves the supply problem. Nat Prod Rep. 2009;26:322\u201337.","journal-title":"Nat Prod Rep"},{"key":"2054_CR7","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1158\/1535-7163.MCT-10-0263","volume":"9","author":"M D'Incalci","year":"2010","unstructured":"D'Incalci M, Galmarini CM. A review of trabectedin (ET-743): a unique mechanism of action. Mol Cancer Ther. 2010;9:2157\u201363.","journal-title":"Mol Cancer Ther"},{"key":"2054_CR8","doi-asserted-by":"crossref","first-page":"2964","DOI":"10.1158\/0008-5472.CAN-04-4037","volume":"65","author":"P Allavena","year":"2005","unstructured":"Allavena P, Signorelli M, Chieppa M, et al. Anti-inflammatory properties of the novel antitumor agent yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production. Cancer Res. 2005;65:2964\u201371.","journal-title":"Cancer Res"},{"key":"2054_CR9","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1158\/0008-5472.CAN-09-2335","volume":"70","author":"G Germano","year":"2010","unstructured":"Germano G, Frapolli R, Simone M, et al. Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells. Cancer Res. 2010;70:2235\u201344.","journal-title":"Cancer Res"},{"key":"2054_CR10","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.ccr.2013.01.008","volume":"23","author":"G Germano","year":"2013","unstructured":"Germano G, Frapolli R, Belgiovine C, et al. Role of macrophage targeting in the antitumor activity of trabectedin. Cancer Cell. 2013;23:249\u201362.","journal-title":"Cancer Cell"},{"key":"2054_CR11","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1158\/1535-7163.MCT-08-0848","volume":"8","author":"C Forni","year":"2009","unstructured":"Forni C, Minuzzo M, Virdis E, et al. Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors. Mol Cancer Ther. 2009;8:449\u201357.","journal-title":"Mol Cancer Ther"},{"key":"2054_CR12","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1200\/JCO.2005.01.180","volume":"23","author":"A Cesne Le","year":"2005","unstructured":"Le Cesne A, Blay JY, Judson I, et al. Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. J Clin Oncol. 2005;23:576\u201384.","journal-title":"J Clin Oncol"},{"key":"2054_CR13","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1200\/JCO.2004.02.098","volume":"22","author":"R Garcia-Carbonero","year":"2004","unstructured":"Garcia-Carbonero R, Supko JG, Manola J, et al. Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J Clin Oncol. 2004;22:1480\u201390.","journal-title":"J Clin Oncol"},{"key":"2054_CR14","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1200\/JCO.2004.05.210","volume":"22","author":"A Yovine","year":"2004","unstructured":"Yovine A, Riofrio M, Blay JY, et al. Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. J Clin Oncol. 2004;22:890\u20139.","journal-title":"J Clin Oncol"},{"key":"2054_CR15","doi-asserted-by":"crossref","first-page":"5484","DOI":"10.1200\/JCO.2005.05.028","volume":"23","author":"R Garcia-Carbonero","year":"2005","unstructured":"Garcia-Carbonero R, Supko JG, Maki RG, et al. Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study. J Clin Oncol. 2005;23:5484\u201392.","journal-title":"J Clin Oncol"},{"key":"2054_CR16","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/1471-2407-13-64","volume":"13","author":"JY Blay","year":"2013","unstructured":"Blay JY, Italiano A, Ray-Coquard I, et al. Long-term outcome and effect of maintenance therapy in patients with advanced sarcoma treated with trabectedin: an analysis of 181 patients of the French ATU compassionate use program. BMC Cancer. 2013;13:64.","journal-title":"BMC Cancer"},{"key":"2054_CR17","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1093\/annonc\/mds659","volume":"24","author":"BL Samuels","year":"2013","unstructured":"Samuels BL, Chawla S, Patel S, et al. Clinical outcomes and safety with trabectedin therapy in patients with advanced soft tissue sarcomas following failure of prior chemotherapy: results of a worldwide expanded access program study. Ann Oncol. 2013;24:1703\u20139.","journal-title":"Ann Oncol"},{"key":"2054_CR18","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1097\/CAD.0b013e328333057b","volume":"21","author":"J Fayette","year":"2010","unstructured":"Fayette J, Boyle H, Chabaud S, et al. Efficacy of trabectedin for advanced sarcomas in clinical trials versus compassionate use programs: analysis of 92 patients treated in a single institution. Anticancer Drugs. 2010;21:113\u20139.","journal-title":"Anticancer Drugs"},{"key":"2054_CR19","doi-asserted-by":"crossref","first-page":"4188","DOI":"10.1200\/JCO.2008.21.0088","volume":"27","author":"GD Demetri","year":"2009","unstructured":"Demetri GD, Chawla SP, von Mehren M, et al. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol. 2009;27:4188\u201396.","journal-title":"J Clin Oncol"},{"key":"2054_CR20","unstructured":"Health Canada. Summary basis of decision (SBD) for prYondelisTM. Health Canada. 2010. http:\/\/www.hc-sc.gc.ca\/dhp-mps\/alt_formats\/pdf\/prodpharma\/sbd-smd\/phase1-decision\/drug-med\/sbd_smd_2010_yondelis_124729-eng.pdf . Accessed July 29, 2015."},{"key":"2054_CR21","unstructured":"European Medicines Agency. Yondelis: EPAR - product information. European Medicines Agency. 2009. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000773\/WC500045832.pdf . Accessed July 29, 2015."},{"key":"2054_CR22","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE), Version 4.03. National Cancer Institute. 2010. http:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf . Accessed July 29, 2015."},{"key":"2054_CR23","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228\u201347.","journal-title":"Eur J Cancer"},{"key":"2054_CR24","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.ejca.2015.01.006","volume":"51","author":"A Cesne Le","year":"2015","unstructured":"Le Cesne A, Ray-Coquard I, Duffaud F, et al. Trabectedin in patients with advanced soft tissue sarcoma: A retrospective national analysis of the French Sarcoma Group. Eur J Cancer. 2015;51:742\u201350.","journal-title":"Eur J Cancer"},{"key":"2054_CR25","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1007\/s10637-011-9662-0","volume":"30","author":"A Cesne Le","year":"2012","unstructured":"Le Cesne A, Yovine A, Blay JY, et al. A retrospective pooled analysis of trabectedin safety in 1,132 patients with solid tumors treated in phase II clinical trials. Invest New Drugs. 2012;30:1193\u2013202.","journal-title":"Invest New Drugs"},{"key":"2054_CR26","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.2217\/fon.14.10","volume":"10","author":"I Gounaris","year":"2014","unstructured":"Gounaris I, Hatcher HM, Davidson D, et al. Trabectedin for advanced soft tissue sarcomas: a single institution experience. Future Oncol. 2014;10:1843\u201351.","journal-title":"Future Oncol"},{"key":"2054_CR27","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/sj.clpt.6100259","volume":"83","author":"J Hing","year":"2008","unstructured":"Hing J, Perez-Ruixo JJ, Stuyckens K, et al. Mechanism-based pharmacokinetic\/pharmacodynamic meta-analysis of trabectedin (ET-743, Yondelis) induced neutropenia. Clin Pharmacol Ther. 2008;83:130\u201343.","journal-title":"Clin Pharmacol Ther"},{"key":"2054_CR28","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2147\/TCRM.S1174","volume":"4","author":"PA Cassier","year":"2008","unstructured":"Cassier PA, Dufresne A, Blay JY, et al. Trabectedin and its potential in the treatment of soft tissue sarcoma. Ther Clin Risk Manag. 2008;4:109\u201316.","journal-title":"Ther Clin Risk Manag"},{"key":"2054_CR29","doi-asserted-by":"crossref","first-page":"56282","DOI":"10.1155\/SRCM\/2006\/56282","volume":"2006","author":"G Huygh","year":"2006","unstructured":"Huygh G, Clement PM, Dumez H, et al. Ecteinascidin-743: evidence of activity in advanced, pretreated soft tissue and bone sarcoma patients. Sarcoma. 2006;2006:56282.","journal-title":"Sarcoma"},{"key":"2054_CR30","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1200\/JCO.2001.19.5.1248","volume":"19","author":"S Delaloge","year":"2001","unstructured":"Delaloge S, Yovine A, Taamma A, et al. Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients--preliminary evidence of activity. J Clin Oncol. 2001;19:1248\u201355.","journal-title":"J Clin Oncol"},{"key":"2054_CR31","doi-asserted-by":"crossref","first-page":"536s","DOI":"10.1200\/jco.2006.24.18_suppl.9568","volume":"24","author":"A Yver","year":"2006","unstructured":"Yver A, Cohen R, Williams D, et al. Assessment of trabectedin (T) induced liver toxicity with correlation to liver morphology in a phase I study of T\u2009+\u2009pegylated liposomal doxorubicin (PLD). J Clin Oncol. 2006;24:536s.","journal-title":"J Clin Oncol"},{"key":"2054_CR32","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1200\/JCO.2001.19.5.1256","volume":"19","author":"A Taamma","year":"2001","unstructured":"Taamma A, Misset JL, Riofrio M, et al. Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors. J Clin Oncol. 2001;19:1256\u201365.","journal-title":"J Clin Oncol"},{"key":"2054_CR33","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.taap.2007.11.020","volume":"228","author":"JK Lee","year":"2008","unstructured":"Lee JK, Leslie EM, Zamek-Gliszczynski MJ, et al. Modulation of trabectedin (ET-743) hepatobiliary disposition by multidrug resistance-associated proteins (Mrps) may prevent hepatotoxicity. Toxicol Appl Pharmacol. 2008;228:17\u201323.","journal-title":"Toxicol Appl Pharmacol"},{"key":"2054_CR34","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1016\/S0959-8049(02)00491-4","volume":"38","author":"AT Oosterom van","year":"2002","unstructured":"van Oosterom AT, Mouridsen HT, Nielsen OS, et al. Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients. Eur J Cancer. 2002;38:2397\u2013406.","journal-title":"Eur J Cancer"},{"key":"2054_CR35","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.ygyno.2009.04.034","volume":"114","author":"DS McMeekin","year":"2009","unstructured":"McMeekin DS, Lisyanskaya A, Crispens M, et al. Single-agent trabectedin as second-line therapy of persistent or recurrent endometrial cancer: results of a multicenter phase II study. Gynecol Oncol. 2009;114:288\u201392.","journal-title":"Gynecol Oncol"},{"key":"2054_CR36","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.clon.2007.05.006","volume":"19","author":"R Roylance","year":"2007","unstructured":"Roylance R, Seddon B, McTiernan A, et al. Experience of the use of trabectedin (ET-743, Yondelis) in 21 patients with pre-treated advanced sarcoma from a single centre. Clin Oncol (R Coll Radiol). 2007;19:572\u20136.","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"2054_CR37","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.3390\/md8102647","volume":"8","author":"T Schmitt","year":"2010","unstructured":"Schmitt T, Keller E, Dietrich S, et al. Trabectedin for metastatic soft tissue sarcoma: a retrospective single center analysis. Mar Drugs. 2010;8:2647\u201358.","journal-title":"Mar Drugs"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-016-2054-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,14]],"date-time":"2020-09-14T04:02:02Z","timestamp":1600056122000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.biomedcentral.com\/1471-2407\/16\/30"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,19]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["2054"],"URL":"https:\/\/doi.org\/10.1186\/s12885-016-2054-2","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1,19]]},"article-number":"30"}}